Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 235 publications
COMBI-I: Long-Term Overall Survival With Spartalizumab Plus Dabrafenib and Trametinib in BRAF V600-Mutant Advanced Melanoma.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: August 12, 2026
Correction: Real-World Outcomes for Patients with Clinically Node-Positive Melanoma Undergoing Neoadjuvant Immunotherapy and Nodal Dissection.
Journal: Annals of surgical oncology
Published: April 24, 2026
ASO Visual Abstract: International Survey on Evidence for Index Lymph Node Surgery Following Neoadjuvant Systemic Therapy for Stage III Melanoma.
Journal: Annals of surgical oncology
Published: January 23, 2026
Optimizing pathological response assessment after neoadjuvant immunotherapy: linking clinical practice to drug development.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: December 12, 2025
A differentiated thyroid carcinoma-specific graded prognostic assessment for brain metastases: derivation in a 10,306-patient cohort and external validation.
Journal: Journal of neuro-oncology
Published: November 03, 2025
Investigating Chronic Toxicity, Diet, Patient-Reported Outcomes and the Microbiome in Immunotherapy-Treated Metastatic Melanoma Survivors: A New Frontier.
Journal: Nutrients
Published: October 31, 2025
Prognostic Factors in Thyroid Cancer Patients With Brain Metastases: A Systematic Review and Meta-Analysis.
Journal: Thyroid : official journal of the American Thyroid Association
Published: September 16, 2025
Germline variants in cancer susceptibility genes among patients with mucosal melanoma.
Journal: NPJ genomic medicine
Published: September 12, 2025
Adjuvant nivolumab and relatlimab in stage III/IV melanoma: the randomized phase 3 RELATIVITY-098 trial.
Journal: Nature medicine
Published: September 12, 2025
Intratumoral Sotigalimab with Pembrolizumab Induces Rapid Activation of Antigen-Presenting Cells and Drives Antitumor Responses in Non-injected Tumors in Metastatic Melanoma: A Phase I/II Study.
Journal: Cancer discovery
Published: September 08, 2025
Lymphodepletion, tumor-infiltrating lymphocytes, and high versus low dose IL-2 followed by pembrolizumab in patients with metastatic melanoma.
Journal: Oncoimmunology
Published: August 15, 2025
International Survey on Evidence for Index Lymph Node Surgery After Neoadjuvant Systemic Therapy for Stage III Melanoma.
Journal: Annals of surgical oncology
Published: August 12, 2025
Last Updated: 09/26/2026